Back HCV Treatment Experimental HCV Drugs AASLD 2013: Daclatasvir + Asunaprevir Cures 85% of Genotype 1b Hepatitis C Patients in Japanese Study

AASLD 2013: Daclatasvir + Asunaprevir Cures 85% of Genotype 1b Hepatitis C Patients in Japanese Study


An interferon- and ribavirin-free oral regimen of daclatasvir plus asunaprevir taken for 24 weeks led to sustained virological response in 85% of Japanese patients with hepatitis C virus subtype 1b, according to findings presented at the 64th AASLD Liver Meeting last week in Washington, DC.

The development of direct-acting antivirals has brought about a revolution in the treatment of chronic hepatitis C virus (HCV) infection. While the first of these new agents were initially approved as add-ons to interferon-based therapy, people with hepatitis C and their providers are eagerly awaiting all-oral regimens that avoid the difficult side effects of interferon.

Kazuaki Chayama from Hiroshima University presented results from a Phase 3 trial (AI447-017) testing an interferon-free regimen of Bristol-Meyers Squibb's HCV NS5A replication complex inhibitor daclatasvir (formerly BMS-790052) plus the NS3 protease inhibitor asunaprevir (formerly BMS-650032) for patients who were either non-responders to prior interferon-based therapy or ineligible for or intolerant of interferon.

The study enrolled 222 chronic hepatitis C patients with HCV subtype 1b, the predominant type in Japan. In contrast with most U.S. and European studies, two-thirds of participants were women and the average age was a bit older at 63 years; 40% were over age 65. Half had the favorable IL28B CC gene variant associated with interferon responsiveness and 10% had liver cirrhosis.

The population included 22% prior null responders (<2 log reduction in HCV RNA), 16% prior partial responders, 45% deemed ineligible to take interferon (for reasons such as pre-existing depression, anemia, other comorbidities, or advanced age), and 16% who were interferon intolerant (previously discontinued interferon before 12 weeks due to toxicities).

All participants in this open-label study received 60 mg once-daily daclatasvir plus 100 mg twice-daily asunaprevir for 24 weeks. They were followed for an additional 24 weeks after finishing treatment to determine sustained virological response (SVR24), or continued undetectable HCV RNA, which is considered a cure.


  • The overall SVR24 rate was 85% in a modified intent-to-treat analysis, broken down to 87% for interferon ineligible or intolerant patients and 81% for prior non-responders.
  • HCV viral load declined rapidly after starting therapy, with 84% of ineligible/intolerant patients and 61% of prior non-responders showing rapid virological response at week 4; 96% and 87%, respectively, had undetectable HCV RNA at the end of therapy.
  • However, 11 ineligible/intolerant patients and six prior non-responders (8%) relapsed during post-treatment follow-up.
  • High sustained response rates were obtained regardless of IL28B status (85% for favorable CC, 85% for intermediate CT, and 83% for least favorable TT).
  • Other baseline factors did not significantly affect response rates.
  • Interestingly, people with cirrhosis did at least as well as non-cirrhotics (91% and 84%, respectively) and patients age 65 and older fared slightly better than younger participants (90% vs 81%).
  • Daclatasvir plus asunaprevirwas generally safe and well-tolerated.
  • Overall, 6% of participants experienced serious adverse events, 7% developed grade 3-4 laboratory abnormalities, and 5% discontinued due to adverse events, with all these outcomes being a bit more common among ineligible/intolerant patients compared to prior non-responders.
  • The most common adverse events were upper respiratory infections (30%), elevated ALT or AST liver enzyme levels (16% and 13%), headache (16%), fever (12%), and diarrhea (10%); anemia was rare (3%).
  • All but 1 of the 11 patients who discontinued early due to side effects did so for elevated ALT or AST, which returned to normal after stopping treatment.

"[The] all-oral combination of daclatasvir and asunaprevir achieved high rates of SVR24 in Japanese patients without treatment options and in patients with no prior response to interferon-based therapy," the researchers concluded. "This all-oral, interferon-free, ribavirin-free regimen was well tolerated with low rates of discontinuation, representing a clinically meaningful improvement in both safety and efficacy compared to current standard of care."

Based on these findings, Bristol-Myers Squibb announced during the conference that it has submitted this first interferon- and ribavirin-free regimen for regulatory approval in Japan, where an estimated 1.2 million people are living with hepatitis C.

While these are good results for people with HCV 1b, studies have shown that the dual regimen of daclatasvir/asunaprevir is not as effective against subtype 1a. (Asunaprevir is also not active against HCV genotypes 2 or 3.)

However, as also reported at the Liver Meeting, adding a third agent -- the non-nucleoside NS5B polymerase inhibitor BMS-791325 -- raised sustained response rates to 91% for people with HCV 1a and 100% for 1b. Bristol-Myers Squibb is working on a fixed-dose combination pill containing these 3 drugs.



K Chayama, Y Suzuki, K Ikeda, et al. All-oral Combination of Daclatasvir Plus Asunaprevir in Interferon Ineligible Naive/Intolerant and Nonresponder Japanese Patients Chronically Infected with HCV Genotype 1b: Results from a Phase 3 Trial. 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2013). Washington, DC, November 1-5, 2013. Abstract211.

Other Source

Bristol-Myers Squibb. BMS Submits First All-Oral, Interferon-Free and Ribavirin-Free Treatment Regimen for Regulatory Review in Japan for Patients with Chronic Hepatitis C Infection. Press release. November 2, 2013.